ACADIA Pharmaceuticals (ACAD) Stock Forecast for 2024–2028. Sell or Buy Prediction







Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …

ACADIA Pharmaceuticals (ACAD) Stock Forecast for 2024–2028. Sell or Buy?

Updated: April 14, 2024 (07:24)

Sector: Healthcare

The share price of ACADIA Pharmaceuticals Inc. (ACAD) now

Latest session on the 12th of April for
ACADIA Pharmaceuticals Inc. is negative
Trading Volume: 1296092
Open: 17.4 /  High: 17.615 /  Low: 16.85
What analysts predict: $29.54
52-week High/Low: $33.99 / $17.56

50/200 Day Moving Average: $22.78 / $25.05

This figure corresponds to the Average Price over the previous 50/200 days. For ACADIA Pharmaceuticals stocks, the 50-day moving average is the resistance level today.

For ACADIA Pharmaceuticals stocks, the 200-day moving average is the resistance level today.

Are you interested in ACADIA Pharmaceuticals Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the ACADIA Pharmaceuticals stock price in 2024, 2025, 2026, 2027, 2028. How much will one ACADIA Pharmaceuticals share be worth in 2024 - 2028?

When should I take profit in ACADIA Pharmaceuticals stock? When should I record a loss on ACADIA Pharmaceuticals stock? What are analysts' forecasts for ACADIA Pharmaceuticals stock? What is the future of ACADIA Pharmaceuticals stock? We forecast ACADIA Pharmaceuticals stock performance using neural networks based on historical data on ACADIA Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

ACADIA Pharmaceuticals stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for ACADIA Pharmaceuticals shares. This happens once a day.


Historical and forecast chart of ACADIA Pharmaceuticals stock

The chart below shows the historical price of ACADIA Pharmaceuticals stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the ACADIA Pharmaceuticals stock price can be found in the table below.

Long-term forecasts by years.

Unveiling Future Prospects of ACAD: A Comprehensive Stock Analysis

Trend: Bearish
Feb 29, 2024

As investors turn their eyes towards Acadia Pharmaceuticals, the near future seems to be knitted with key factors bound to sway the ACAD stock rates significantly. Notably, the spotlight shines on the DAYBUE drug, where its slow uptake and dwindling usage in 2024 hints at waning demand. This trajectory isn't just a shallow hiccup but a potential red flag affecting revenue streams and growth prospects, laying the groundwork for analysts to project the stock's direction meticulously.

Dissecting the Core Factors Influencing ACAD's Financial Fate

Another piece in this intricate puzzle is DAYBUE’s efficacy and side effects profile. With reports of many patients experiencing scant to non-existent improvement, coupled with a not insignificant showcase of side effects, discontinuation rates could soar. This disheartening performance can be the linchpin for analysts forecasting stiffer times ahead for ACAD's stock.

The narrative deepens with key insiders resigning and offloading shares, broadcasting possible internal turmoil or loss of confidence in ACAD's future. This perception alone could dampen investor enthusiasm, further affecting stock prices. Additionally, DAYBUE's underperformance weighs heavily on ACAD's cash flow, underlining the company's vulnerability and sharpening the focus for accurate stock rate predictions.

To decipher ACAD's stock rate trajectory accurately, analysts must weave together these elements: DAYBUE's market acceptance, its side effects and efficacy juxtaposition, insider confidence via their shareholding actions, and the company's financial resilience. Mapping these factors grants us a window into ACAD's future, enabling informed, albeit cautious, investment strategies.

  • Slow uptake and diminishing usage of DAYBUE
  • Impact of DAYBUE’s side effects and limited effectiveness
  • Insider actions and investor sentiment
  • Cash flow concerns tied to DAYBUE's performance
Review the original Analysis
About author

The Tumultuous Road Ahead for ACAD Stocks: Navigating Through Uncertainty

Trend: Bearish
Mar 12, 2024

Investors holding stakes in Acadia Pharmaceuticals are sitting on the edge of their seats as a confluence of pivotal events promises to significantly sway the ACAD stock rates in the near future. The failure of pimavanserin in a Phase 3 study aimed at treating the negative symptoms of schizophrenia has sent shockwaves through the market, hinting at a challenging road ahead for the company's flagship asset. This major setback not only casts a shadow over the drug's efficacy and market potential but also raises questions about the company's valuation and future revenue streams.

Forecasting the Future: Key Influencers on ACAD Stocks

For analysts looking to forecast changes in ACAD's stock price with precision, understanding the gravity and implications of recent events becomes crucial. Several key factors stand out:

  • The collapse of pimavanserin in crucial trials implies a significant blow to revenue projections and market confidence, positioning it as the most critical factor in future stock evaluations.
  • Previous rejections by the FDA for other indications further compound the skepticism surrounding pimavanserin's viability.
  • The looming expiration of pimavanserin's patent protection in 2030 introduces anxiety over impending competition and the erosion of market exclusivity.
  • While the market potential of Daybue for treating Rett Syndrome remains a wild card, its success or failure could also influence stock valuation, albeit to a lesser extent than the aforementioned factors.

Given these considerations, analysts equipped with a nuanced understanding of these elements are better positioned to predict ACAD's stock trajectory accurately. The road ahead for ACAD stocks is fraught with uncertainty, but by closely monitoring these developments, one can glean insights into the company's capacity to navigate through these tumultuous times.

Review the original Analysis
About author

The ACADIA Stock Rollercoaster: Predictions and Prospects

Trend: Bullish
Mar 13, 2024

Investing in ACADIA Pharmaceuticals (ACAD) has been akin to riding a rollercoaster, with recent events sending investors holding on tight. The ACAD stock forecast has seen better days, particularly following the disappointing results from pimavanserin's schizophrenia trials. This setback, pivotal in the pharma world, plunged the stock value by 20%, casting shadows on the ACAD stock buy or sell debate. Amidst these challenges, analysts and investors alike are keen on understanding what lies ahead for ACAD's stock rates.

Key Factors Shaping ACADIA's Financial Future

Several critical factors loom over the horizon, with the potential to sway ACAD stock price predictions. Firstly, ongoing sales and revenue growth from its approved drugs, Nuplazid and Daybue, remain critical to the company's valuation. As these figures climb, they can reassure investors about ACAD's market viability, influencing whether ACAD is a good stock to buy. Additionally, the protection of Nuplazid's patents against generic competition until at least 2030 serves as another linchpin. Successful defence of these patents could secure ACADIA's revenue stream, quietly bolstering the ACADIA Pharmaceuticals stock forecast.

Lastly, market sentiment, often a reflection of the collective investor psyche, wields the power to rapidly shift the ACAD stock price target. Analysts looking to make accurate projections must keep a pulse on insider and institutional investor movements, as these groups' confidence (or lack thereof) can serve as a bellwether for ACAD stock's direction. By evaluating these factors, an analyst can offer a grounded ACAD stock price prediction, navigating the tumultuous waters of pharmaceutical investing with a clearer vista.

In summary, while the why ACAD stock down question looms large, the company's ability to rebound hinges on pivotal developments in sales, patent litigation, and market sentiment. For those pondering the buy or sell ACADIA Pharmaceuticals stock question, these are the indicators to watch closely.

Review the original Analysis
About author

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, specializes in the development and commercialization of small molecule drugs designed to meet unmet medical needs in diseases of the central nervous system.

ACADIA Pharmaceuticals daily forecast for a month

Date Target Pes. Opt. Vol., %
Apr 16 17.03 16.59 17.46 5.26
Apr 17 17.25 16.82 17.49 3.98
Apr 18 16.76 16.25 16.96 4.33
Apr 19 16.36 15.89 16.86 6.09
Apr 20 16.03 15.60 16.37 4.89
Apr 21 16.38 16.18 16.74 3.44
Apr 22 16.48 16.08 16.87 4.96
Apr 23 16.17 15.90 16.69 4.96
Apr 24 15.87 15.60 16.33 4.68
Apr 25 15.83 15.64 16.11 3.04
Apr 26 16.05 15.64 16.44 5.09
Apr 27 15.85 15.72 16.11 2.50
Apr 28 16.17 15.76 16.63 5.54
Apr 29 16.43 16.29 16.79 3.07
Apr 30 16.43 15.99 16.64 4.07
May 01 17.07 16.55 17.60 6.35
May 02 17.08 16.82 17.39 3.41
May 03 17.47 16.96 17.97 5.93
May 04 17.77 17.33 18.09 4.39
May 05 17.38 16.98 17.52 3.19
May 06 17.48 17.04 17.84 4.68
May 07 17.82 17.68 18.26 3.31
May 08 17.92 17.36 18.34 5.61
May 09 18.09 17.60 18.54 5.35
May 10 18.77 18.33 19.15 4.47
May 11 18.48 18.27 18.74 2.59
May 12 18.80 18.36 19.12 4.18
May 13 19.00 18.83 19.50 3.55
May 14 18.80 18.35 19.37 5.53
May 15 18.17 17.80 18.48 3.80

ACADIA Pharmaceuticals Daily Price Targets


ACADIA Pharmaceuticals Stock Forecast 04-16-2024.

Forecast target price for 04-16-2024: $17.03.
Negative dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 4.994%.
Pessimistic target level: 16.59
Optimistic target level: 17.46

ACADIA Pharmaceuticals Stock Forecast 04-17-2024.

Forecast target price for 04-17-2024: $17.25.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.828%.
Pessimistic target level: 16.82
Optimistic target level: 17.49

ACADIA Pharmaceuticals Stock Forecast 04-18-2024.

Forecast target price for 04-18-2024: $16.76.
Negative dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 4.152%.
Pessimistic target level: 16.25
Optimistic target level: 16.96

ACADIA Pharmaceuticals Stock Forecast 04-19-2024.

Forecast target price for 04-19-2024: $16.36.
Negative dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 5.743%.
Pessimistic target level: 15.89
Optimistic target level: 16.86

ACADIA Pharmaceuticals Stock Forecast 04-20-2024.

Forecast target price for 04-20-2024: $16.03.
Negative dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 4.661%.
Pessimistic target level: 15.60
Optimistic target level: 16.37

ACADIA Pharmaceuticals Stock Forecast 04-21-2024.

Forecast target price for 04-21-2024: $16.38.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.327%.
Pessimistic target level: 16.18
Optimistic target level: 16.74

ACAD (ACAD) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
May. 18.59 17.68 19.15 7.69
Jun. 17.85 16.25 18.28 11.13
Jul. 17.02 16.16 17.96 10.01
Aug. 15.71 15.22 16.13 5.61
Sep. 14.09 13.53 14.94 9.40
Oct. 14.33 13.28 15.00 11.46
Nov. 13.91 13.35 15.22 12.29
Dec. 14.13 13.72 14.67 6.47

ACADIA Pharmaceuticals forecast for this year


ACADIA Pharmaceuticals Stock Prediction for May 2024

An uptrend is forecast for this month with an optimal target price of $18.5903. Pessimistic: $17.68. Optimistic: $19.15


ACADIA Pharmaceuticals Stock Prediction for Jun 2024

An downtrend is forecast for this month with an optimal target price of $17.8541. Pessimistic: $16.25. Optimistic: $18.28


ACADIA Pharmaceuticals Stock Prediction for Jul 2024

An downtrend is forecast for this month with an optimal target price of $17.0186. Pessimistic: $16.16. Optimistic: $17.96


ACADIA Pharmaceuticals Stock Prediction for Aug 2024

An downtrend is forecast for this month with an optimal target price of $15.7115. Pessimistic: $15.22. Optimistic: $16.13


ACADIA Pharmaceuticals Stock Prediction for Sep 2024

An downtrend is forecast for this month with an optimal target price of $14.0901. Pessimistic: $13.53. Optimistic: $14.94


ACADIA Pharmaceuticals Stock Prediction for Oct 2024

An uptrend is forecast for this month with an optimal target price of $14.3268. Pessimistic: $13.28. Optimistic: $15.00


ACADIA Pharmaceuticals Stock Prediction for Nov 2024

An downtrend is forecast for this month with an optimal target price of $13.9142. Pessimistic: $13.35. Optimistic: $15.22


ACADIA Pharmaceuticals Stock Prediction for Dec 2024

An uptrend is forecast for this month with an optimal target price of $14.1313. Pessimistic: $13.72. Optimistic: $14.67



ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 13.32 12.09 14.15 14.57
Feb 13.54 13.18 14.08 6.35
Mar 12.92 12.60 13.42 6.12
Apr 12.10 10.95 12.74 14.02
May 12.28 11.57 12.57 7.97
Jun 12.54 11.79 13.34 11.62
Jul 12.06 11.08 13.04 15.09
Aug 11.96 11.04 12.40 10.99
Sep 12.37 11.90 13.37 11.00
Oct 12.72 12.06 13.10 7.92
Nov 13.19 12.27 14.33 14.36
Dec 13.01 11.98 13.97 14.20

ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 13.25 12.04 14.09 14.55
Feb 13.57 12.98 14.04 7.54
Mar 14.33 13.75 15.67 12.29
Apr 14.88 14.19 16.03 11.48
May 14.49 13.34 14.99 11.02
Jun 13.74 12.46 14.39 13.41
Jul 13.21 12.31 13.85 11.11
Aug 11.96 11.56 12.68 8.83
Sep 10.76 9.89 11.35 12.85
Oct 10.48 9.70 10.94 11.27
Nov 10.06 9.22 10.95 15.76
Dec 10.17 9.45 10.69 11.64

ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 10.60 10.26 11.06 7.25
Feb 11.29 10.80 12.13 10.95
Mar 12.12 11.78 13.06 9.80
Apr 13.34 12.52 14.30 12.43
May 13.44 12.78 13.89 8.01
Jun 13.90 12.95 14.85 12.80
Jul 13.67 12.75 14.72 13.37
Aug 12.28 11.88 13.04 8.92
Sep 11.61 10.61 12.60 15.81
Oct 11.29 10.51 11.70 10.19
Nov 11.28 10.94 12.29 11.01
Dec 12.31 11.29 13.08 13.67

ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 13.03 11.98 13.92 13.93
Feb 13.42 13.00 13.94 6.70
Mar 12.86 12.09 13.77 12.21
Apr 13.12 12.30 14.05 12.44
May 12.40 12.02 12.75 5.72
Jun 11.85 11.14 12.68 12.21
Jul 11.19 10.53 11.85 11.11
Aug 10.33 9.44 11.09 14.87
Sep 10.15 9.76 10.67 8.56
Oct 9.85 9.10 10.76 15.49
Nov 9.38 8.66 9.73 10.99
Dec 9.27 8.89 10.13 12.19

ACADIA Pharmaceuticals information and performance

ACADIA Pharmaceuticals Address

3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO, CA, US

Market Capitalization: 2 967 544 000 $

Market capitalization of the ACADIA Pharmaceuticals Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ACAD shares in the company outstanding by the market price of one share.

EBITDA: -67 827 000 $

EBITDA of ACADIA Pharmaceuticals is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: -0.42

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -0.37

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.693
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 27.7

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 3.558

Enterprise Value (EV) /Revenue

EV To EBITDA: -38.11

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 164772000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.